BR112012023877A2 - dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal - Google Patents

dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal

Info

Publication number
BR112012023877A2
BR112012023877A2 BR112012023877A BR112012023877A BR112012023877A2 BR 112012023877 A2 BR112012023877 A2 BR 112012023877A2 BR 112012023877 A BR112012023877 A BR 112012023877A BR 112012023877 A BR112012023877 A BR 112012023877A BR 112012023877 A2 BR112012023877 A2 BR 112012023877A2
Authority
BR
Brazil
Prior art keywords
dapsone
therapy
airway inflammation
aerosolized
mucociliary transport
Prior art date
Application number
BR112012023877A
Other languages
English (en)
Portuguese (pt)
Inventor
Bruce K Rubin
Soichiro Kanoh
Tsuyoshi Tanabe
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of BR112012023877A2 publication Critical patent/BR112012023877A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012023877A 2010-03-15 2011-03-08 dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal BR112012023877A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31387710P 2010-03-15 2010-03-15
US41635310P 2010-11-23 2010-11-23
PCT/US2011/027494 WO2011115778A2 (en) 2010-03-15 2011-03-08 Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport

Publications (1)

Publication Number Publication Date
BR112012023877A2 true BR112012023877A2 (pt) 2016-08-02

Family

ID=44649767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023877A BR112012023877A2 (pt) 2010-03-15 2011-03-08 dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal

Country Status (8)

Country Link
US (3) US20130005822A1 (enExample)
EP (1) EP2547335A4 (enExample)
JP (1) JP5908884B2 (enExample)
KR (1) KR101924162B1 (enExample)
AU (1) AU2011227613B2 (enExample)
BR (1) BR112012023877A2 (enExample)
CA (1) CA2793170C (enExample)
WO (1) WO2011115778A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619321A (zh) * 2012-04-06 2015-05-13 Uab研究基金会 用于增加cftr活性的方法
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物
CA3126367A1 (en) * 2020-03-30 2021-09-30 Pulmonem Inc. Dapsone formulations and methods of using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675633B2 (en) 1991-12-18 1997-02-13 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
GB9820886D0 (en) 1998-09-26 1998-11-18 Glaxo Group Ltd Inhalation device
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6572858B1 (en) * 1999-04-30 2003-06-03 Apt Pharmaceuticals, Llc Uses for anti-malarial therapeutic agents
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US7077130B2 (en) 2000-12-22 2006-07-18 Chrysalis Technologies Incorporated Disposable inhaler system
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
JP4933046B2 (ja) 2002-09-06 2012-05-16 フィリップ モーリス ユーエスエー インコーポレイテッド 液体エアロゾル製剤、エアロゾル発生装置およびエアロゾル発生方法
US7497214B2 (en) 2002-09-16 2009-03-03 3M Innovative Properties Company Aerosol dispensers and adaptors therefor
EP1549770B1 (en) * 2002-09-30 2008-03-12 Novartis AG Methods to predict cholesterol elevations during immunosuppressant therapy
US20040086469A1 (en) * 2002-10-30 2004-05-06 Osborne David W. Protectant for UV-induced skin damage
US7683029B2 (en) 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
EP1670787B1 (en) * 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
MXPA06004499A (es) * 2003-10-21 2006-06-27 Pharmacia Corp Metodo para el tratamiento o la prevencion de inflamacion respiratoria con un inhibidor de ciclooxigenasa 2 en combinacion con un inhibidor de fosfodiesterasa 4 y sus composiciones.
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
ES2775825T3 (es) * 2008-02-27 2020-07-28 Allergan Inc Dapsona para tratar la rosácea
WO2010099523A1 (en) * 2009-02-27 2010-09-02 University Of Cincinnati Method of treating reactive airway disease

Also Published As

Publication number Publication date
KR101924162B1 (ko) 2018-11-30
WO2011115778A2 (en) 2011-09-22
JP5908884B2 (ja) 2016-04-26
WO2011115778A9 (en) 2012-01-12
CA2793170A1 (en) 2011-09-22
CA2793170C (en) 2018-04-17
JP2013522295A (ja) 2013-06-13
EP2547335A4 (en) 2014-04-16
KR20130055580A (ko) 2013-05-28
AU2011227613A1 (en) 2012-10-04
US20130005822A1 (en) 2013-01-03
EP2547335A2 (en) 2013-01-23
US20180243213A1 (en) 2018-08-30
US20150040894A1 (en) 2015-02-12
AU2011227613B2 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
CL2013002542A1 (es) Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas.
CR20150150A (es) Inhibidores de glucosilceramida sintasa
PH12015501108B1 (en) Treatment of pulmonary disease
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112015024869A2 (pt) administração nasal
EP2749280A3 (en) Combination of glycopyrronium and formoterol
BR112015003742A2 (pt) sistema de montagem de componente de descarga
BR112013001119A2 (pt) composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
IN2014DN09326A (enExample)
PE20150171A1 (es) Nueva forma de dosificacion y formulacion de abediterol
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
BR112012004692B8 (pt) solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano
BRPI1008227A8 (pt) composição de glicocorticoide inalável para uso na terapia de um paciente que sofre de asma severa e sem controle.
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
BR112014030910A2 (pt) pó seco para formulação de inalação compreendendo xinafoato de salmeterol, propionato de fluticasona e brometo de tiotrópio e método para preparar o mesmo
MX350793B (es) Pirroldicarboxamidas condensadas y su uso como agentes farmaceuticos.
BR112016002317A2 (pt) métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumab
BR112012023877A2 (pt) dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal
UY32482A (es) Método o sistema que usa biomarcadores para el seguimiento de un tratamiento
BR112014005730A2 (pt) método de tratar carcinoma mucoepidermóide
GEP20186863B (en) Pharmaceutical composition for use in increasing the trophism of nasal mucosa
CL2014002339A1 (es) Forma cristalina c de succinato de ester dipropilcarbamoilmetilo del acido 3-(3-{2-[(e)-3,5-diamino-6-cloro-pirazina-2-carbonilimino]-1,3,8-triaza-espiro[4.5]decano-8-carbonil}-bencenosulfonilamino)-propionico; composicion farmaceutica y dispositivo de inhalacion que la comprende; y su uso para el tratamiento de enfermedades respiratorias tales como epoc y asma.
GEP20186809B (en) Combination therapy agent for treating rhinitis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.